Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The International Journal of Neuroscience|February 15, 2012
A 17-year experience of abobotulinumtoxina in cervical dystoniaFrancisco Vivancos-Matellano, Isabel Ybot-Gorrin, Exuperio Diez-Tejedor
Neuro-Ophthalmology (Aeolus Press)|November 20, 2019
Efficacy and Safety of Long-Term Therapy with Type A Botulinum Toxin in Patients with BlepharospasmFrancisco Vivancos-Matellano, Ana Rodríguez-Sanz, Yolanda Herrero-Infante, et al.
Clinical Neurology and Neurosurgery|March 4, 2021
Hemifacial spasm through the last three decades: From etiology to efficacy and safety of long-term botulinum toxin treatmentYolanda Herrero-Infante, Ana Rodríguez-Sanz, Jorge Máñez-Miró, et al.
Acta Otorrinolaringologica Espanola|May 3, 2018
Clinical experience with patients with spasmodic dysphonia and primary Meige syndromeMaría Fernanda Pedrero-Escalas, Isabel García-López, Susana Santiago-Pérez, et al.
The Neurologist|November 3, 2011
Assessment of Parkinson disease: what do we need to show neuroprotection?Isabel Ybot-Gorrin, Francisco Vivancos-Matellano, José Rafael Chacón-Peña, et al.
The Neurologist|May 3, 2011
Rheumatoid meningitis mimicking progressive supranuclear palsyMaria Jose Aguilar-Amat, Maria Jose Abenza-Abildúa, Francisco Vivancos, et al.
Journal of Clinical Epidemiology|June 9, 2005
The SCOPA-Motor Scale for assessment of Parkinson's disease is a consistent and valid measurePablo Martínez-Martín, Julián Benito-León, Juan A Burguera, et al.
Movement Disorders Clinical Practice|May 8, 2019
The Parkinson's Disease Sleep Scale-2 (PDSS-2): Validation of the Spanish Version and Its Relationship With a Roommate-Based VersionPablo Martinez-Martin, John B Wetmore, Carmen Rodríguez-Blázquez, et al.
Movement Disorders Clinical Practice|November 7, 2022
Validation of the OPTIMIPARK Questionnaire: A Tool to Optimize Treatment in Parkinson's DiseaseJorge U Máñez-Miró, Francisco Vivancos-Matellano, Fernando Alonso-Frech, et al.
Pageof 1